◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › VERU

Veru Inc. (VERU) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-10

Veru Inc. (VERU) operates in the Biotechnology industry and is headquartered in Miami, United States with about 20 employees. Its market capitalization is roughly $45 million. In the fiscal year ended 2025-09-30, VERU reported $0M in revenue and ($23M) in net income.

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally.

Interactive charts & full statements →

VERU Revenue & Earnings History — Annual Income Statement

Income statement2025-09-302024-09-302023-09-302022-09-302021-09-30
Total Revenue$0M$0M$16M$39M
Gross Profit$6M$8M$31M$48M
Operating Income (EBIT)($36M)($37M)($96M)($84M)
Net Income($23M)($38M)($93M)($84M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VERU Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($7M)($5M)($8M)($8M)($9M)
Net Income($3M)($5M)$2M($7M)($8M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VERU Free Cash Flow History

VERU Balance Sheet History

Balance sheet2025-09-302024-09-302023-09-302022-09-302021-09-30
Total Assets$30M$60M$50M$135M
Total Liabilities$12M$28M$30M$53M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VERU viewer.

Other Companies in Biotechnology

← VERIAll stocksVERX →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.